DK1223980T3 - Anvendelse af CSF-1-inhibitorer - Google Patents
Anvendelse af CSF-1-inhibitorerInfo
- Publication number
- DK1223980T3 DK1223980T3 DK00972422T DK00972422T DK1223980T3 DK 1223980 T3 DK1223980 T3 DK 1223980T3 DK 00972422 T DK00972422 T DK 00972422T DK 00972422 T DK00972422 T DK 00972422T DK 1223980 T3 DK1223980 T3 DK 1223980T3
- Authority
- DK
- Denmark
- Prior art keywords
- csf
- inhibitors
- medicament
- preparing
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT181399 | 1999-10-28 | ||
| PCT/AT2000/000281 WO2001030381A2 (de) | 1999-10-28 | 2000-10-25 | Verwendung von csf-1-inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1223980T3 true DK1223980T3 (da) | 2003-09-15 |
Family
ID=3521549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00972422T DK1223980T3 (da) | 1999-10-28 | 2000-10-25 | Anvendelse af CSF-1-inhibitorer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090317403A1 (da) |
| EP (1) | EP1223980B1 (da) |
| JP (2) | JP4307775B2 (da) |
| AT (1) | ATE240744T1 (da) |
| AU (1) | AU783063B2 (da) |
| CA (1) | CA2388298C (da) |
| DE (1) | DE50002293D1 (da) |
| DK (1) | DK1223980T3 (da) |
| ES (1) | ES2197885T3 (da) |
| PT (1) | PT1223980E (da) |
| WO (1) | WO2001030381A2 (da) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1223980B1 (de) * | 1999-10-28 | 2003-05-21 | Hofbauer, Reinhold | Verwendung von csf-1-inhibitoren |
| US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| JP2005525314A (ja) * | 2002-01-03 | 2005-08-25 | トランジェーヌ、ソシエテ、アノニム | 抗腫瘍療法のために使用可能な組み合わせ物 |
| ES2345885T3 (es) | 2002-11-15 | 2010-10-05 | Novartis Vaccines And Diagnostics, Inc. | Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer. |
| GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| BRPI0506726B8 (pt) * | 2004-01-07 | 2021-05-25 | Chiron Corp | anticorpo monoclonal específico para m-csf e usos deste |
| US8652469B2 (en) | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
| WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| NZ587830A (en) | 2008-03-14 | 2012-08-31 | Transgene Sa | Antibody against the colony-stimulating factor-1 receptor (CSF-1R) |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
| GB0910833D0 (en) * | 2009-06-23 | 2009-08-05 | Univ Edinburgh | Avian genes |
| CN105218672A (zh) | 2009-12-10 | 2016-01-06 | 霍夫曼-拉罗奇有限公司 | 优先结合人csf1r胞外域4的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CN112480256A (zh) | 2010-05-04 | 2021-03-12 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| ES2618828T3 (es) | 2011-07-18 | 2017-06-22 | The University Of Melbourne | Uso de antagonistas de c-Fms |
| CA2853889A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| BR112015004426A2 (pt) | 2012-08-31 | 2018-08-28 | Five Prime Therapeutics, Inc. | método para reduzir o nível, tratar uma condição, tratar uma condição inflamatória, tratar distúrbio de cd16+, tratar um respondente inadequado de metotrexate, tratar um respondente inadequado de inibidor de tnf, indentificar um sujeito, predizer responsividade e métodos para tratar uma condição inflamatória |
| MX2015014198A (es) | 2013-04-12 | 2015-12-11 | Morphosys Ag | Anticuerpos cuyo objetivo es m-csf. |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| BR112016029460A2 (pt) | 2014-06-23 | 2017-10-24 | Five Prime Therapeutics Inc | métodos para tratar artrite reumatoide |
| IL251464B2 (en) | 2014-10-29 | 2023-03-01 | Five Prime Therapeutics Inc | Combination therapy for cancer |
| BR112017013111A2 (pt) | 2014-12-22 | 2018-05-15 | Five Prime Therapeutics Inc | métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo |
| JP6971850B2 (ja) | 2015-04-13 | 2021-11-24 | ファイヴ プライム セラピューティクス インク | がんの併用療法 |
| SG10202002131PA (en) | 2015-05-21 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| MY195000A (en) * | 2015-05-27 | 2022-12-30 | Ucb Biopharma Sprl | Method for the treatment of neurological disease |
| EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与 |
| CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| CN121159691A (zh) | 2017-05-12 | 2025-12-19 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| KR20240042244A (ko) | 2017-05-19 | 2024-04-01 | 신닥스 파마슈티컬스, 인크. | 조합 요법 |
| CA3073531A1 (en) | 2017-09-13 | 2019-03-21 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| EA202090817A1 (ru) | 2017-10-13 | 2020-09-08 | Харпун Терапьютикс, Инк. | Триспецифические белки и способы их применения |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022238386A1 (en) | 2021-05-10 | 2022-11-17 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるcd40およびcd137に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4504586A (en) * | 1983-02-03 | 1985-03-12 | Amgen | Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1 |
| US5556620A (en) * | 1985-02-05 | 1996-09-17 | Cetus Oncology Corporation | Use of recombinant colony stimulating factor-1 to enhance wound healing |
| US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| CA2132091C (en) * | 1992-04-03 | 2008-09-16 | Kyung J. Kim | Antibodies to alphavbeta3 integrin |
| WO1999032148A1 (en) * | 1997-12-19 | 1999-07-01 | Beth Israel Deaconess Medical Center | Methods and compositions for inhibiting tumor cell growth |
| EP1223980B1 (de) * | 1999-10-28 | 2003-05-21 | Hofbauer, Reinhold | Verwendung von csf-1-inhibitoren |
-
2000
- 2000-10-25 EP EP00972422A patent/EP1223980B1/de not_active Revoked
- 2000-10-25 ES ES00972422T patent/ES2197885T3/es not_active Expired - Lifetime
- 2000-10-25 DK DK00972422T patent/DK1223980T3/da active
- 2000-10-25 DE DE50002293T patent/DE50002293D1/de not_active Expired - Lifetime
- 2000-10-25 JP JP2001532798A patent/JP4307775B2/ja not_active Expired - Lifetime
- 2000-10-25 WO PCT/AT2000/000281 patent/WO2001030381A2/de not_active Ceased
- 2000-10-25 AT AT00972422T patent/ATE240744T1/de active
- 2000-10-25 PT PT00972422T patent/PT1223980E/pt unknown
- 2000-10-25 AU AU11145/01A patent/AU783063B2/en not_active Expired
- 2000-10-25 CA CA2388298A patent/CA2388298C/en not_active Expired - Lifetime
-
2009
- 2009-01-05 JP JP2009000183A patent/JP2009143930A/ja active Pending
- 2009-05-13 US US12/465,490 patent/US20090317403A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1223980A2 (de) | 2002-07-24 |
| EP1223980B1 (de) | 2003-05-21 |
| JP4307775B2 (ja) | 2009-08-05 |
| WO2001030381A3 (de) | 2001-12-06 |
| AU783063B2 (en) | 2005-09-22 |
| DE50002293D1 (de) | 2003-06-26 |
| CA2388298A1 (en) | 2001-05-03 |
| JP2003525870A (ja) | 2003-09-02 |
| AU1114501A (en) | 2001-05-08 |
| CA2388298C (en) | 2013-05-14 |
| ES2197885T3 (es) | 2004-01-16 |
| ATE240744T1 (de) | 2003-06-15 |
| PT1223980E (pt) | 2003-10-31 |
| US20090317403A1 (en) | 2009-12-24 |
| WO2001030381A2 (de) | 2001-05-03 |
| JP2009143930A (ja) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1223980T3 (da) | Anvendelse af CSF-1-inhibitorer | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| AU7031500A (en) | Therapeutic quinazoline compounds | |
| CY2013020I1 (el) | Η χρηση μιας ενωσης ινγκενανης για την κατασκευη ενος φαρμακου για την θεραπεια του καρκινου | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| EA200300544A1 (ru) | Эффективные противоопухолевые лекарственные средства | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| CY1112753T1 (el) | Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743 | |
| DE60223254D1 (de) | Verzögert freisetzende formulierungen von oxymorphon | |
| ATE472325T1 (de) | Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen | |
| NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
| IT1319202B1 (it) | Farmaci per le malattie a base infiammatoria. | |
| DE60100625D1 (de) | Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina | |
| CY1106122T1 (el) | Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση της νοσου ευepεθιστου εντερου | |
| DE50201780D1 (de) | Halogensubstituierte aminodicarbonsäurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen | |
| ATE296827T1 (de) | Heteropolycyclische inhibitoren | |
| DE60026491D1 (de) | Melagatran zur behandlung von entzündungen | |
| IT1318667B1 (it) | Medicamento antinfiammatorio. | |
| GB9907571D0 (en) | Compounds | |
| ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
| EA200200853A1 (ru) | Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака | |
| SE0004827D0 (sv) | Therapeutic compounds | |
| ITRM990719A0 (it) | Uso di ubichinone q10 per il trattamento locale e la prevenzione di patalogie aftalmologiche secondarie alla terapia fotorefrattiva, chirurg | |
| CY1105142T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων |